Insiders who have reported open-market trades at the same companies as Thomas K. Equels. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Ted D. Kellner - $50K in AIM purchases and sales on record
Thomas K. Equels is a corporate insider, tracked as CEO & President, Director of AIM ImmunoTech Inc. (AIM). InsiderAlpha holds 11 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Thomas K. Equels submitted recently?
6 primary Form 4 filings in the last 90 days, covering 1 company.
Has Thomas K. Equels been buying or selling stock?
Recorded transactions: 9 open-market purchases ($56K) and 0 open-market sales across all tracked filings.
Thomas K. Equels is CEO & President, Director of AIM ImmunoTech Inc. (AIM). 11 SEC Form 4 filings on record going back to 2024, most recently on 26 October 2026. Most recent open-market trade: bought $5K of AIM on 26 October 2026. Lifetime open-market purchases: $56K.
Recent transactions
10
The latest 10 SEC Form 4 transactions reported by Thomas K. Equels.
InsiderAlpha's records for Thomas K. Equels go back to 2024: 11 primary Form 4 filings, an average of 3.7 per year. The typical open-market purchase is $6K (9 buys totaling $56K). The largest single buy on record is $17K of AIM in 2024. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
